Investor Event Attendance and Presentation

RNS Number : 7237L

Open Orphan PLC

10 September 2019

 

10 September 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at the ShareSoc Growth Company Seminar and the London South East Biotech Investor Evening

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that on Wednesday 11^th September the Company will be attending and presenting at the ShareSoc Growth Company Seminar at 65 Gresham Street, London, EC2V 7NQ from 17:30 and will also be attending and presenting at the London South East Biotech Investor Evening at Brewers Hall, Aldermanbury Square, London EC2V 7HR from 18:30.

Cathal Friel, Open Orphan's Chief Executive Officer, will be in attendance throughout both events and will be presenting to update existing and potential investors on the Company's business plans for 2019-2020.

The events will provide an opportunity for investors to hear about the progress being made by the Company following the reverse takeover of Venn Life Sciences and the potential for Open Orphan moving forward.

A link to the presentation will be made available on the Company website following the events.

For further information on the events, please visit the respective event website:

-       https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-london-11-september-2019/

-       https://www.lse.co.uk/events/ 

Enquiries:

Open Orphan Plc Tel: [phone]
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

 

END

 

 

NRAUGUMGBUPBGQB